Advertisement

Ovarian Cancer Medications

Here's a list of the approved drugs to treat ovarian cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG RECOMMENDATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Lupron
GENERIC NAME leuprolide
DRUG RECOMMENDATION

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

DRUG Tamoxifen
GENERIC NAME tamoxifen
DRUG RECOMMENDATION

Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Zoladex
GENERIC NAME goserelin
DRUG RECOMMENDATION

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Avastin
GENERIC NAME bevacizumab
DRUG RECOMMENDATION

Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer and ovarian, fallopian tube or primary peritoneal cancer. Mvasi is a biosimilar medication.

DRUG Lynparza
GENERIC NAME olaparib
DRUG RECOMMENDATION

Lynparza is a PARP inhibitor approved for first-line maintenance treatment of ovarian cancer in women with harmful BRCA mutations, maintenance treatment of recurrent ovarian cancer that is responding to chemotherapy, previously treated advanced ovarian cancer in patients with BRCA mutations, and previously treated HER2-negative metastatic breast cancer in people with BRCA mutations.

DRUG Rubraca
GENERIC NAME rucaparib
DRUG RECOMMENDATION

Rubraca is a PARP inhibitor approved for maintenance treatment of women with recurrent ovarian, fallopian tube or primary peritoneal cancer that is responding to chemotherapy and for previously treated cancer in patients with harmful BRCA mutations.

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG RECOMMENDATION

Vitrakvi is a tropomyosin receptor kinase (TRK) inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

DRUG Zejula
GENERIC NAME niraparib
DRUG RECOMMENDATION

Zejula is a PARP inhibitor approved for maintenance treatment of women with recurrent ovarian, fallopian tube or primary peritoneal cancer that is responding to chemotherapy.

Advertisement

Hot topics